Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
Copanlisib Expanded Access Program (EAP) for Patients Who, in the Opinion of Their Healthcare Provider, Are Deriving Benefit From Copanlisib Therapy
Sponsor: Bayer
Listed as NCT06238583, this observational or N/A phase trial focuses on Cancer and remains ongoing. Sponsored by Bayer, it has been updated 4 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Sep 2025 — Present [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2024 — Jul 2024 [monthly]
No Longer Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Multiple Locations, Brazil , Multiple Locations, Chile , Multiple Locations, Hong Kong , Multiple Locations, Hungary , Multiple Locations, Ireland , Multiple Locations, Malaysia , Multiple Locations, Poland , Multiple Locations, Romania , Multiple Locations, Russia , Multiple Locations, Taiwan and 1 more location